CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30

Citius Pharmaceuticals, Inc.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.43−0.03 (-7.00%)

Close on Oct 19, 2026

Market cap: $11.20M
P/E (TTM): –
Dividend yield: –

Citius Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q3 2026 2026-06-30	Q2 2026 2026-03-31	Q1 2026 2025-12-31	Q4 2025 2025-09-30	Q3 2025 2025-06-30	Q2 2025 2025-03-31	Q1 2025 2024-12-31	Q4 2024 2024-09-30	Q3 2024 2024-06-30	Q2 2024 2024-03-31	Q1 2024 2023-12-31	Q4 2023 2023-09-30	Q3 2023 2023-06-30	Q1 2023 2022-12-31	Q4 2022 2022-09-30	Q3 2022 2022-06-30	Q2 2022 2022-03-31	Q1 2022 2021-12-31	Q4 2021 2021-09-30	Q3 2021 2021-06-30	Q2 2021 2021-03-31	Q1 2021 2020-12-31	Q4 2020 2020-09-30	Q3 2020 2020-06-30	Q2 2020 2020-03-31	Q1 2020 2019-12-31	Q4 2019 2019-09-30	Q3 2019 2019-06-30	Q2 2019 2019-03-31	Q1 2019 2018-12-31	Q4 2018 2018-09-30	Q3 2018 2018-06-30	Q2 2018 2018-03-31	Q1 2018 2017-12-31	Q4 2017 2017-09-30	Q3 2017 2017-06-30	Q2 2017 2017-03-31	Q1 2017 2016-12-31	Q4 2016 2016-09-30	Q3 2016 2016-06-30
Cash & Equivalents	17	4.59	7.72	4.25	6.09	0.03	1.10	3.25	18	13	20	26	33	37	42	48	56	65	70	116	104	4.30	14	8.52	4.34	2.78	7.89	4.51	3.20	7.04	9.18	2.76	5.01	7.37	3.20	0.20	0.06	0.05	0.29	1.63
Cash & Short-Term Investments	17	4.59	7.72	4.25	6.09	0.03	1.10	3.25	18	13	20	26	33	37	42	48	56	65	70	116	104	4.30	14	8.52	4.34	2.78	7.89	4.51	3.20	7.04	9.18	2.76	5.01	7.37	3.20	0.20	0.06	0.05	0.29	1.63
Receivables	0.69	1.08	4.05	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Inventory	23	23	23	22	17	15	14	8.27	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	3.01	3.36	3.54	1.40	1.31	3.01	2.85	2.70	10	9.01	7.86	7.89	7.83	5.43	2.85	2.79	2.50	2.52	2.74	1.27	1.28	1.28	0.12	0.05	0.05	0.06	0.05	0.05	0.05	0.05	0.06	0.07	0.06	0.11	0.22	0.36	0.28	0.44	0.60	0.39
Other Current Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	19	19	19	19	19
Total Current Assets	43	32	38	28	25	18	18	14	28	22	28	34	41	42	45	51	58	68	73	117	105	5.58	14	8.57	4.39	2.84	7.94	4.56	3.25	7.09	10	2.83	5.07	7.48	3.42	0.56	0.34	0.49	0.89	2.02
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.01	–	–	–	0.01	–
Accumulated Depreciation	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	0.00	0.00
Operating Lease Right-of-Use Assets	0.75	0.79	0.84	0.82	0.88	0.92	0.19	0.25	0.30	0.35	0.40	0.45	0.50	0.60	0.65	0.69	0.74	0.78	0.82	0.86	0.91	0.95	0.99	1.03	1.06	1.10	1.14	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	9.35	1.59	1.59	9.35	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59	1.59
Other Long-Term Assets	98	100	102	102	102	102	102	102	–	–	–	69	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Assets	142	133	140	131	128	121	121	117	97	91	97	104	110	112	114	120	128	138	142	147	135	35	44	38	26	25	37	26	24	28	31	24	26	28	24	22	21	21	22	23
Accounts Payable	8.04	9.45	11	14	10	9.37	7.36	4.93	1.66	2.67	2.65	2.93	3.08	1.54	1.17	1.69	1.71	1.79	1.28	1.35	1.13	0.98	1.86	1.81	1.52	1.55	2.71	2.43	1.93	2.08	1.57	0.91	1.40	0.56	0.60	1.98	1.86	0.99	0.91	0.31
Accrued Expenses	26	24	4.69	4.19	8.52	8.78	6.24	0.02	0.55	0.15	0.28	0.48	0.89	0.69	1.41	1.30	1.34	3.14	0.62	0.37	0.24	0.25	0.16	0.16	0.15	0.21	0.25	0.16	0.18	0.20	0.18	0.12	0.14	0.62	0.56	0.65	1.86	1.85	0.96	0.59
Short-Term Debt	300	300	300	300	300	300	300	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Current Debt	300	300	300	300	300	300	300	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.18	0.17	0.15	0.09	0.11	0.15	0.20	0.24	0.24	0.23	0.22	0.22	0.21	0.20	0.20	0.19	0.19	0.18	0.18	0.17	0.17	0.16	0.16	0.15	0.15	0.15	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	52	55	38	45	52	50	45	36	4.15	4.17	5.58	5.78	5.79	4.54	4.53	4.46	4.02	7.34	3.98	3.60	2.98	3.55	4.10	3.61	3.11	3.63	4.61	4.04	3.36	3.90	3.18	2.19	2.56	2.62	2.47	9.97	7.34	6.32	5.18	4.85
Long-Term Debt	6.41	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.16	0.16	0.16	0.16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	0.59	0.64	0.68	0.72	0.77	0.79	–	0.02	0.08	0.15	0.20	0.26	0.32	0.43	0.48	0.53	0.58	0.63	0.68	0.72	0.77	0.81	0.86	0.90	0.94	0.98	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.77	0.81	0.83	0.81	0.88	0.93	0.20	0.26	0.32	0.37	0.43	0.48	0.53	0.63	0.68	0.72	0.77	0.81	0.86	0.90	0.94	0.98	1.01	1.05	1.09	1.12	1.14	–	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	7.70	7.80	8.04	7.77	7.51	7.24	6.98	6.71	6.57	6.43	6.28	6.14	5.99	5.71	5.56	4.99	4.99	4.99	4.99	4.99	4.99	4.99	4.99	4.99	–	–	4.99	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	66	63	47	53	60	58	52	43	11	11	12	12	12	11	11	9.98	9.59	13	9.65	9.31	8.90	9.51	10	9.66	4.05	4.61	9.59	1.26	0.59	1.13	0.41	2.19	2.56	2.62	2.47	9.97	7.34	6.32	5.18	4.85
Total Debt	306	300	300	300	300	300	300	–	–	–	–	–	–	–	–	–	–	–	–	–	0.16	0.16	0.16	0.16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Common Stock	0.03	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.18	0.16	0.16	0.01	0.16	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.13	0.06	0.06	0.05	0.04	0.03	0.03	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01	0.08	0.07	0.00	0.07
Additional Paid-In Capital	344	330	327	306	296	283	277	271	276	259	256	253	250	234	232	231	230	229	228	228	210	106	104	95	87	80	80	74	69	68	68	59	59	57	50	36	36	35	34	33
Retained Earnings	-277	-268	-247	-239	-231	-222	-211	-201	-191	-180	-171	-162	-152	-133	-130	-122	-113	-105	-96	-91	-85	-81	-71	-66	-65	-60	-53	-52	-48	-44	-40	-37	-35	-31	-28	-25	-22	-20	-17	-15
Shareholders' Equity	67	62	80	68	65	61	65	70	86	79	85	91	98	100	103	110	118	124	132	137	125	–	34	29	25	23	27	24	24	27	31	22	24	26	22	12	14	15	17	18
Noncontrolling Interest	9.30	7.54	14	9.98	2.50	2.92	3.51	4.02	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	0.60	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Equity	76	69	93	78	68	64	69	74	86	80	85	91	0.10	101	103	110	118	125	133	137	126	26	34	29	25	23	27	24	24	27	31	22	24	26	22	12	14	15	17	18
Total Liabilities & Equity	142	133	140	131	128	121	121	117	97	91	97	104	110	112	114	120	128	138	142	147	135	35	44	38	26	25	37	26	24	28	31	24	26	28	24	22	21	21	22	23
Shares Outstanding(shares)	27	22	22	18	14	8.76	7.73	7.25	7.23	6.36	6.36	6.35	6.35	5.85	5.85	5.85	5.85	5.84	5.84	5.84	5.39	2.22	2.22	1.85	1.52	1.21	1.16	0.88	0.75	0.71	0.65	0.43	0.43	0.40	0.33	0.20	0.20	0.20	0.20	0.19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.84
Debt to equity: 4.60
Debt to assets: 215.4%
Cash to current liabilities: 32.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.17
Dividend yield: –